Cameron Santoro

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, explored the intricate management of alopecia areata, often in tandem with other autoimmune conditions while emphasizing the significance of innovative medications and diagnostic tools, such as dermoscopy, in enhancing patient outcomes.

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SERDs to improve patient outcomes.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, particularly regarding immune-related adverse events.

Kristen Whitney, DO, FAAD, dermatologist at Allegheny Health Network, highlighted recent breakthroughs in treating alopecia areata, focusing on the effectiveness of Janus kinase inhibitors and the ongoing challenges related to insurance coverage and patient access.

The COVID-19 pandemic required an evolution of traditional nursing practices, but the unpredictability led to increased stress, burnout, and job dissatisfaction.

Alopecia areata was more likely to develop in patients with inflammatory bowel disease (IBD) who were taking anti–tumor necrosis factor (TNF) therapy at the onset of the condition.

Alopecia areata is more prevalent in Hispanic, Asian/Pacific Islander, and Black children than in non-Hispanic White children, with some Asian subgroups having a higher risk compared with those of Chinese ethnicity.

Biosimilar aflibercept (P041) demonstrated comparable safety and efficacy to the originator aflibercept (Eylea) in treating patients with retinal conditions like neovascular age-related macular degeneration (nAMD).

Alopecia areata and asthma are strongly linked, particularly through the inflammatory protein IL-33, suggesting a shared biological pathway and potential for targeted treatments like dupilumab.

Biosimilars offer significant cost-saving potential while expanding patient access, particularly in oncology and immunology.

The Medicaid budget survey for fiscal years 2024 and 2025 revealed state predictions are expecting a decline in Medicaid enrollment and an increase in spending next year due to the end of pandemic-era policies and federal funding.

Medicaid expansion is associated with improved care and increased survival rates for patients with certain breast cancers, but future studies should focus on whether Medicaid expansion mitigates the disparities between Black and non-White patients.

Mabel Mardones, MD, board-certified medical oncologist and hematologist who specializes in breast cancer at Rocky Mountain Cancer Centers, emphasizes the importance in identifying patients with HR-positive, HER2-negative (HR+/HER2–) breast cancer with unmet treatment needs.

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses advancements in breast cancer treatment, highlighting CDK4/6 inhibitors and antibody-drug conjugates as promising alternatives to traditional therapies.

Glenn Balasky, executive director of Rocky Mountain Cancer Centers, emphasizes the need for government support to sustain telehealth and suggested a hybrid model combining centralized high-tech care with remote monitoring to address the challenges of providing innovative care in rural settings.

Upadacitinib, a drug used to treat atopic dermatitis (AD), may potentially induce alopecia areata, a case study suggests.

Artificial intelligence can revolutionize drug discovery by expediting development, reducing costs, and improving treatment options, but addressing its limitations is crucial for future success.

Adalimumab biosimilar market shares have steadily increased, but challenges remain due to pricing strategies and limited government support, according to the Samsung Bioepis report.

Alopecia areata is linked to specific trace elements, serum metabolites, and inflammatory factors, according to a genetic analysis, suggesting potential new treatment and prevention strategies.

Here are 5 key points for pre–breast screening preparation that cover the areas of risk assessment, lifestyle adjustments, understanding screening details, managing anxiety, and open provider communication.

CMS actuaries foresee a gradual rise in per capita health spending, slowing initially but eventually outpacing economic growth.

The Heart Failure Society of America (HFSA) annual meeting 2024 was scheduled to showcase groundbreaking research on the impact of COVID-19 on patients with myocarditis and heart failure.

Blue Shield of California will offer an adalimumab biosimilar at a price that is 75% less than the reference product Humira for the monthly dose.

The legacy of redlining continues to harm minority health, with Black individuals facing higher rates of health issues, linked to environmental factors and limited access to resources in regions previously redlined.

The American Cancer Society (ACS) 2024 report emphasizes significant racial disparities in breast cancer outcomes and calls for increased efforts to improve equity in screening and treatment.

Speakers at the 2024 International Myeloma Society (IMS) conference share the updates from the myeloma space that they were most excited about this year.

A French study found that follitropin alfa, a biosimilar fertility drug, is more cost-effective compared with its originator, leading to potential savings for both patients and the health care system.

Binod Dhakal, MD, associate professor, division of hematology and oncology, Medical College of Wisconsin and lead investigator of the CARTITUDE-4 study, presented updated data at the 2024 International Myeloma Society conference.

Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in Oncology, compares the AURIGA trial with other studies on maintenance therapy for patients with multiple myeloma.

Saad Z. Usmani, MD, MBA, FACP, myeloma specialist and cellular therapist at Memorial Sloan Kettering Cancer Center, presented the results of the CEPHEUS trial and emphasized the positive impact daratumumab has on patients with multiple myeloma.